Abstract: Objective: To investigate the protein expression of E-cad and PTEN in normal endometria (NE), atypical hyperplasia endometria (AHE) and carcinoma endometria (CE) and to evaluate their clinical value. Methods: A total of 37 cases with NE, 40 cases of AHE and 72 cases of CE were studied by immunohistochemical methods. Results: In NE, AHE and CE, the positive rate of E-cad was 100%, 70.00% and 47.22%, and positive rate of PTEN was 100%, 77.50% and 48.61%, respectively. The expression of E-cad was related with staging, myometrial invasion and the grades: E-cad expression in stageⅠ~Ⅱ, G₁~G₂ and myometrial invasion ≤1/2 was higher than that in stageⅢ~Ⅳ, G₃ and invasion >1/2 (P<0.05). The expression of PTEN was related with staging and the grades: PTEN expression in stageⅠ~Ⅱwas lower than that in stage Ⅲ~Ⅳ (P<0.05). Its expression in G₁~G₂ was higher than that in G₃ (P<0.05). The overall 5-year survival rate of high expression group of E-cad and PTEN was higher than that of lowexpression group (P<0.05). Conclusion: E-cad and PTEN may play an important role in origin, development and prognosis of endometrial carcinoma.